Search
ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial
Following ASCO 24, we update our detailed analysis of the current phase late-stage ADC data from AZN/Daiichi’s TROPION Gilead’s EVOKE and MRK/SKB’s program in Lung Cancer and still find steep obstacles that may be too high to surmount...
![CYTK BMY](https://static.wixstatic.com/media/f1a3c6_147cdd3f7415483c8a1cf52af5793021~mv2.jpg/v1/fill/w_980,h_1365,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/f1a3c6_147cdd3f7415483c8a1cf52af5793021~mv2.jpg)
Comments